GlassScriptPhysician profile
Brooke Renae Huff
NPI 1508369687
$6,534.34
in general payments reported to CMS, 2019-2025
25 companies · $2,993 in 2025
The $2,993 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $438 · 2022: $539 · 2023: $801 · 2024: $1,762 · 2025: $2,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,152 · Education: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,152.41 |
| Education | $404.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,143.59 | 2021-2025 | |
| Janssen Biotech, INC. | $1,080.01 | 2024-2025 | Tremfya |
| Ucb, INC. | $849.28 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $582.81 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $572.65 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $453.36 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $381.25 | 2021-2025 | Odomzo, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $246.61 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $229.81 | 2024-2025 | Ebglyss, Taltz |
| Amgen INC. | $197.98 | 2022-2025 | Otezla, Otezla |
| Incyte Corporation | $144.01 | 2022-2025 | Opzelura |
| Pfizer INC. | $128.44 | 2022-2024 | |
| Galderma Laboratories, L.P. | $72.53 | 2024-2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $69.99 | 2021 | |
| Biofrontera INC. | $64.82 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $59.30 | 2022-2025 | Seysara |
| Arcutis Biotherapeutics, INC. | $55.35 | 2024-2025 | Zoryve |
| Organon LLC | $54.91 | 2025 | Vtama |
| Botanix Sb INC | $32.70 | 2025 | Sofdra |
| Sensus Healthcare, INC. | $31.66 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.36 | 2025 | |
| Mayne Pharma Commercial LLC | $15.73 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $15.62 | 2025 | Nuzyra |
| Cipher Pharmaceuticals US LLC | $15.32 | 2025 | Spinosad, Natroba |
| Helsinn Therapeutics (U.S.), INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Huff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.